FDA Approves At-Home Use of FluMist Vaccine

The FDA has approved the FluMist nasal spray vaccine for at-home use, making it the first influenza vaccine that can be self-administered or given by caregivers without healthcare provider supervision. This decision allows adults aged 18-49 and caregivers for children aged 2-17 to receive the vaccine conveniently at home, following a prescription process. FluMist, initially approved in 2003 for healthcare administration, offers a live attenuated form of the virus and has been found to be comparably effective to the traditional flu shot. The nasal spray will be available for home delivery beginning next flu season, aiming to improve vaccination rates, which typically hover around 50%. Experts believe this new availability could increase participation in flu vaccination, but further data will be needed to assess its impact. The manufacturer will provide an online platform for screening and eligibility before shipping the vaccine directly to consumers.